{"entity":{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","aka":["Melanoma of mucous membranes","Sinonasal melanoma","Oral mucosal melanoma","Anorectal melanoma","Vulvovaginal melanoma"],"tldr":"Mucosal melanoma grows on the moist linings of the nose, mouth, anus or genital tract rather than on sun-exposed skin, so it is found late and carries fewer of the mutations that make skin melanoma visible to the immune system. Immunotherapy helps less often than in skin melanoma; a minority of tumours has a KIT mutation that the pill imatinib can target.","summary":"Mucosal melanoma arises from melanocytes in the sinonasal tract, oral cavity, anorectum, vulva, vagina and, rarely, the urinary tract, biliary tree and oesophagus. It is not caused by ultraviolet light and its genome differs from cutaneous melanoma: a low mutation burden, frequent structural rearrangements and amplifications, KIT mutations or amplifications in a substantial minority, SF3B1 mutations, and BRAF V600 mutations in only about one in twenty. Presentation is late because the sites are hidden, and most patients have thick, often ulcerated or multifocal primaries; five-year survival is well below that of cutaneous melanoma at any stage.\n\nSurgery is the mainstay for localised disease, but local recurrence is frequent and radical operations at head and neck or anorectal sites carry heavy morbidity, so postoperative radiotherapy is often added to improve local control even though it has not lengthened survival. In China, where the disease is common, a randomised trial found adjuvant temozolomide-cisplatin chemotherapy improved relapse-free and overall survival over high-dose interferon and observation, and it remains an option there. Sentinel node biopsy is less standardised than in cutaneous disease.\n\nImmunotherapy works less well than in cutaneous melanoma: in the pooled analysis of the nivolumab trials the response rate was 23 percent with nivolumab alone and 37 percent with nivolumab plus ipilimumab, and pembrolizumab produced responses in 19 percent in the pooled KEYNOTE analysis. Chinese investigators combined toripalimab with the VEGF receptor inhibitor axitinib and reported responses in nearly half of chemotherapy-naive patients in phase 1b, and the pairing is being tested in randomised trials. Imatinib produces responses in roughly one in four tumours with KIT exon 11 or 13 mutations, and the MEK inhibitor tunlametinib is approved in China for NRAS-mutant melanoma, a group that includes many mucosal tumours.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Mucosal_melanoma","links":[{"label":"Pooled nivolumab analysis in mucosal melanoma (JCO 2017)","url":"https://ascopubs.org/doi/10.1200/JCO.2016.67.9258"},{"label":"Toripalimab plus axitinib (JCO 2019)","url":"https://ascopubs.org/doi/10.1200/JCO.19.00210"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Mucosal_melanoma"}],"tags":["subtype-page"],"related":["acral-melanoma","advanced-melanoma","vulvar"],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors","imrt-igrt"],"targets":["kit","pd1","ctla4","mek"],"drugs":["nivolumab","ipilimumab","pembrolizumab","imatinib","toripalimab","axitinib","tunlametinib"],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"skin","burden":"Mucosal melanoma is about one in a hundred melanomas in Europe and North America but roughly a fifth of melanomas in China, where it is the second commonest subtype; it arises in the nose and sinuses, mouth, anus and rectum, and vulva and vagina, and is usually found late.","subtypes":["Sinonasal and oral mucosal melanoma (head and neck)","Anorectal mucosal melanoma","Vulvar and vaginal mucosal melanoma","KIT-mutant mucosal melanoma (imatinib candidates)","NRAS-mutant mucosal melanoma (MEK inhibitor trials)","Mucosal melanoma in East Asian populations (toripalimab-axitinib approach)"],"biomarkers":["KIT mutation or amplification (exon 11 and 13 predict imatinib response)","NRAS mutation","BRAF V600 mutation (uncommon)","SF3B1 mutation","Low tumour mutational burden","PD-L1 expression (weakly predictive)"],"standardOfCare":[{"setting":"Localised disease","approach":"Wide surgical excision with the least morbid operation that clears margins; postoperative radiotherapy for head and neck and anorectal primaries to improve local control.","refs":["wide-local-excision","imrt-igrt"],"guideline":{"version":"NCCN Guidelines: Melanoma: Cutaneous","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492"}},{"setting":"Adjuvant","approach":"Anti-PD-1 antibody as for cutaneous stage III disease by extrapolation; temozolomide-cisplatin chemotherapy is an option in China on a randomised trial.","refs":["nivolumab","pembrolizumab","temozolomide","cisplatin"],"guideline":{"version":"NCCN Guidelines: Melanoma: Cutaneous","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492"}},{"setting":"Advanced, first line","approach":"Nivolumab plus ipilimumab (higher response than nivolumab alone in the pooled analysis) or anti-PD-1 monotherapy; toripalimab with axitinib in China.","refs":["nivolumab","ipilimumab","pembrolizumab","toripalimab","axitinib"],"guideline":{"version":"NCCN Guidelines: Melanoma: Cutaneous","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492"}},{"setting":"KIT-mutant disease","approach":"Imatinib for exon 11 or 13 mutations after or alongside immunotherapy; nilotinib is an alternative.","refs":["imatinib","nilotinib","kit"],"guideline":{"version":"NCCN Guidelines: Melanoma: Cutaneous","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492"}},{"setting":"NRAS-mutant disease","approach":"Tunlametinib (approved in China) or MEK inhibitor trials; naporafenib with trametinib in the SEACRAFT-2 trial.","refs":["tunlametinib","nct06008106","seacraft-2","naporafenib"]}],"stateOfArt":["Immunotherapy doublets produce responses in about a third of patients, roughly half the rate seen in cutaneous melanoma.","KIT is the one recurrent drug target and imatinib the one approved kinase inhibitor that works in a subset.","China, where the disease is common, leads the trials of immunotherapy combined with anti-angiogenic drugs."],"history":[{"year":2006,"title":"Curtin and Bastian: KIT alterations found in mucosal and acral melanoma","refs":["kit"]},{"year":2011,"title":"Imatinib phase 2 trials show responses in KIT-mutant melanoma","refs":["imatinib"]},{"year":2013,"title":"Chinese randomised trial: adjuvant temozolomide-cisplatin beats interferon","refs":["temozolomide","cisplatin","interferon-alfa"]},{"year":2017,"title":"Pooled nivolumab analysis: lower response rates in mucosal melanoma","refs":["nivolumab","ipilimumab"]},{"year":2019,"title":"Toripalimab plus axitinib phase 1b reports responses in nearly half","refs":["toripalimab","axitinib"]},{"year":2024,"title":"Tunlametinib approved in China for NRAS-mutant melanoma","refs":["tunlametinib"]}],"pipeline":["toripalimab","axitinib","tunlametinib","nct06008106","seacraft-2","imatinib","lifileucel"],"openProblems":["No phase 3 trial has been run specifically in mucosal melanoma outside China.","Local control at head and neck and anorectal sites is poor without mutilating surgery.","The low mutation burden limits immunotherapy and there is no approved drug for the common structural alterations."],"parent":"melanoma"},"route":"/cancers/mucosal-melanoma/","neighbours":{"cancer":[{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"},{"id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/"},{"id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"},{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/"}],"pathway":[{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"trial":[{"id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/"},{"id":"nct06008106","kind":"trial","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","route":"/trials/nct06008106/"}],"term":[{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/"}]}}